Itric oxide production, Free radical generation as hydrogen peroxide generation andItric oxide production, Free radical

Itric oxide production, Free radical generation as hydrogen peroxide generation and
Itric oxide production, Free radical generation as hydrogen peroxide generation and through altered NF-B based cell signal transduction pathway. Although there is paucity of information on the carcinogenic effect of STZ on humans, when being used, it should be regarded for practical purposes as if it were carcinogenic to humans. Finally, researchers using diabetic animal models for their research should consider the effect of fasting for the interpretation of their results.Competing interest The authors declare that they have no competing interests. Authors’ contributions The study was designed and implemented by ECO, EKC, CS and EU. All authors read and approved the final manuscript. Author details 1 Department of Biochemistry, National Root Crops Research Institute, Umudike, Umuahia, Abia State, Nigeria. FT011 site 2Department of Biochemistry, Michael Okpara University of Agriculture, Umudike, Umuahia, Abia State, Nigeria.References 1. Dolan ME: Inhibition of DNA repair as a means of increasing the antitumor activity of DNA active agents. Adv Drug Del Rev 1997, 26:105?18. 2. Vivek KS: Streptozotocin: an experimental tool in diabetes and alzheimer’s disease (A- Review). Int J Pharma Res Dev 2010, 2(1):1?. 3. Lenzen S: Alloxan and streptozotocin diabetes. Diabetologia 2007, 51:216?26. 4. Rakieten L, Rakieten ML, Nadkarni MV: Studies on the diabetogenic action of Streptozotocin (NSC-37917). Cancer Chem Rep 1963, 29:91?8. 5. Rerup CC: Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 1970, 22:485?18. 6. Bolzan AD, Bianchi MS: Genotoxicity of Streptozotocin. Mutat Res 2002, 512:121?34. 7. Reusser F: Mode of Action of Streptozotocin. J of Bact 1971, 105:580?88. 8. Junod A, Lambert AE, Orci L, Pictet R, Gonet AE, REnold AE: Studies of the diabetogenic action of streptozotocin. Proc Soc Exp Biol Med 1967, 126:201?05. 9. Ventura-Sobrevilla J, Boone-Villa VD, Aguilar CN, Rom -Ramos R, Vega- ila E, Campos-Sep veda E, Alarc -Aguilar F: Effect of Varying Dose and Administration of Streptozotocin on Blood Sugar in Male CD1 Mice. Proc West Pharmacol Soc 2011, 54:5?. 10. Povoski SP, McCullough PJ, Zhou H, Bell RH: Induction of diabetes mellitus in Syrian golden hamsters using stored equilibrium solutions of Streptozotocin. Lab Animal Sci 1993, 43:310?14. 11. Sharma S, et al: Experimental Models of Diabetes. Int J Res Ayurveda and Pharm 2010, 1(2):292?01. 12. Joo HL, Si HY, Jung MOH, Myung GL: Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol 2010, 62:1?3. 13. Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen S: Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetolgia 2007, 43:1528?533. 14. Eleazu CO, Iroaganachi M, Eleazu KC: Ameliorative Potentials of Cocoyam (Colocasia esculenta L.) and Unripe Plantain (Musa paradisiaca L.) on the Relative Tissue Weights of Streptozotocin-Induced Diabetic Rats. J Diabetes Res 2013a 2013, 2013(160964):8. doi:10.1155/2013/1609640. 15. Valentovic MA, Alejandro N, Betts CA, Brown PI, Ramos K: Streptozotocin (STZ) diabetes enhances benzo(alpha)pyrene PubMed ID: induced renal injury in Sprague Dawley rats. Toxicol Lett 2006, 164:214?20. 16. Ferrer J, Benito C, Gomis R: Pancreatic islet GLUT 2 glucose transporter mRNA and protein expression in humans with and without NIDDM. Diabetes 1995, 44:1369?374. 17. Koehn J, et al: Multiple.